ESH Video

International Conference Erythropoiesis Control and Ineffective Erythropoiesis: from bench to bedside

International Conference Erythropoiesis Control and Ineffective Erythropoiesis: from bench to bedside
March 15 - March 17, 2019 - Budapest, Hungary
Chairs : Maria Domenica Cappellini, Stuart Orkin, Valeria Santini


ESH International Conference

Erythropoiesis Control and Ineffective Erythropoiesis: from Bench to Bedside
Chairs: Maria Domenica Cappellini (Milan), Stuart Orkin (Boston), Valeria Santini (Florence)

March 15-17, 2019 – Budapest, Hungary 


A. Programme description

The main objective of this conference is to translate recent, novel data from basic research on the origin and developmental control of mega/erythroid progenitors in haematopoiesis to clinical practice. Erythropoiesis is a complex multistep process extending from committed erythroid progenitors to mature red cells and involving a talk to talk process with other haematopoietic progenitors. Although some recent advances now make it possible to characterize some components of erythropoiesis, much still remains to be investigated, in particular as regards pathological erythropoiesis and in the haematological conditions characterized by ineffective erythropoiesis. During erythropoiesis, efficient cytoprotective systems are required to limit possible ROS-related toxic effects: these systems play an even more important role in conditions of ineffective erythropoiesis (IE), such as thalassaemias, sickle cell disease and congenital dyserythropoietic anaemias (CDAs), but also in myelodysplastic syndromes (MDS). Blood transfusion therapy or treatments with erythropoiesis stimulating agents (ESAs), such as recombinant EPO, are so far the frontline therapies for anaemia associated with ineffective erythropoiesis (IE). However, both treatments are not without risk, and in some cases they are not effective. Therefore, there is a clinical need for novel agents supporting IE with different mechanism(s) of action from existing ESAs.


The meeting is structured with the specific aim to be translational “from bench to bedside”, and to involve participants in lively interactive discussions. It offers a unique opportunity to discuss basic science in a clinical context. This approach will notably involve the presentation and discussion of challenging clinical cases.

The two and half day programme includes 9 sessions that will alternate basic science and clinical practice, with a focus on specific diseases such as CDAs, thalassaemia, SCD, haemolytic anaemias and MDS. More specifically session I on erythropoiesis control will elucidate the role of transcription factors, the single cell gene expression in erythroid commitment/development and the proteolytic remodeling of red cell. Session II will focus on the weight of ineffective erythropoiesis in determining the phenotype expression of different diseases (i.e. thalassaemia, SCD, MDS). Session III will complete this comprehensive focus on insights into the molecular causes of ineffective erythropoiesis. Session IV will be very interactive, with a focus on the presentation of case studies characterized by the clinical consequences of IE. Session V is focused on haemoglobin switching which represents an ideal model to improve our understanding of the different mechanisms of gene regulation, especially the mechanisms of switch genes off and on. Session VI will be very clinical with practical advice for the optimal management of emergency events in patients with different types of red cell disorders. The last 3 sessions are dedicated to new therapeutic approaches to erythroid disorders, mainly targeting IE.

The speakers are eminent international experts in their field. 


B. Educational Objectives

Upon completion of this CME activity, participants should:

  • Understand the mechanisms that control erythropoiesis in the context of haematopoiesis
  • Identify the different causes of ineffective erythropoiesis
  • Translate the basic information in clinical practice in order to understand the different phenotype expressions of diseases such as thalassaemias, SCD, haemolytic anaemias and MDS
  • Be updated on the development of new drugs targeting ineffective erythropoiesis and the state of the art in clinical setting
  • Acquire skills in diagnosis and treatment of erythropoietic abnormalities in different haematological disorders.





Abstract submission





Saturday, March 16th, 2019

From 12:50 to 13:50 
CHAIR: Maria-Domenica Cappellini (Milan)
SPEAKERS: Olivier Hermine
(Paris), Alan List (Tampa)
 This symposium is organised by Celgene.


Accommodation at special conference rates is available at the Marriott Budapest Hotel, where the conference will take place.

Please click here to proceed with your reservation in this hotel (Reservations guaranteed at negotiated prices until January 14th, 2019).

The price of a room : 190€ per night




Budapest Marriott Hotel

Apáczai Csere János u. 4

1052 Hungary

Corporate partners

With the support of



Level 1 Conference Partner



Level 2 Conference Partner




With the support of




Supporting Partner 











Educational Grants



The registration fee for this conference is:
– Regular registration fee: 600€
– Registration fee for resident in-training: 300€ (support document required)

This fee includes :
Your place in the Conference Room,
Conference Materials,
Luncheons, Refreshments throughout the conference.

Your seat in the conference will be definitively reserved upon receipt of your fee.

Type of payment :

A) By Cheque :
ESH, Centre Hayem, Hôpital Saint Louis
1 Avenue Claude Vellefaux
75475 Paris Cedex 10

B) By Bank transfer :
Bank address: BNPParibas, 156 avenue Parmentier, 75010 Paris, France
Bank code: 30004. 
Agency code: 01730.
Account number: 00010099772. 
Control key: 92.
IBAN: FR 76 3000 4017 3000 0100 9977 292

C) By Credit card : VISA, MASTERCARD, AMEX

Cancellation policy of registration fee :
In case of cancellation, up until one month prior to the beginning of the meeting, your registration fee will be reimbursed in full (less bank charges).
If the cancellation is notified between 1 and 30 days prior to the beginning of the meeting, 50% of the registration fee will be reimbursed (less bank charges).
Cancellations notified during the meeting will not be reimbursed.

Register Here